SCHEMBL17470095

SCHEMBL17470095

CNC(=O)c1cc(COc2cnc(Nc3ccc(N4C[C@@H](C)N[C@@H](C)C4)cc3)nc2)c(F)c(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 9/20 0.54
▸ FGFR4 P22455 4/20 0.43
▸ KDR P35968 1/20 0.43
▸ FGFR3 P22607 9/20 0.42
▸ FGFR2 P21802 4/20 0.42
▸ NTRK1 P04629 1/20 0.42
▸ RET P07949 1/20 0.42
▸ PDGFRB P09619 1/20 0.42
▸ MARK3 P27448 1/20 0.42
▸ TNK2 Q07912 1/20 0.42
▸ DDR1 Q08345 1/20 0.42
▸ MAP4K2 Q12851 1/20 0.42
▸ MAP3K11 Q16584 1/20 0.42
▸ DDR2 Q16832 1/20 0.42
▸ MARK2 Q7KZI7 1/20 0.42
▸ MAP4K3 Q8IVH8 1/20 0.42
▸ MAP4K1 Q92918 1/20 0.42
▸ AURKB Q96GD4 1/20 0.42
▸ EIF2AK1 Q9BQI3 1/20 0.42
▸ MAP3K20 Q9NYL2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17537641 0.92 FGFR1 (0.53) FGFR1FGFR4KDRFGFR3FGFR2
SCHEMBL17470065 0.91 FGFR3 (0.52) FGFR1FGFR4KDRFGFR3FGFR2
SCHEMBL16070226 0.91 FGFR3 (0.51) FGFR1FGFR4KDRFGFR3FGFR2
SCHEMBL17470138 0.91 FGFR1 (0.63) FGFR1FGFR4FGFR3FGFR2NTRK1
SCHEMBL17470200 0.91 FGFR3 (0.44) FGFR1FGFR4KDRFGFR3FGFR2
SCHEMBL16050076 0.91 FGFR1 (0.49) FGFR1FGFR4KDRFGFR3FGFR2
SCHEMBL17470145 0.90 KCNH2 (0.51) FGFR1FGFR4KDRFGFR3TNK2
SCHEMBL16053170 0.90 FGFR1 (0.48) FGFR1FGFR4KDRFGFR3FGFR2
SCHEMBL17470064 0.89 FGFR3 (0.52) FGFR1FGFR4KDRFGFR3TNK2
SCHEMBL17469987 0.88 FGFR1 (0.45) FGFR1FGFR3KCNH2BCL6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9701680-B2 Pyrimidine and pyridine compounds and their usage HUTCHISON MEDIPHARMA LIMITED (CN) 2017-07-11 — — US disclosed
US-20160052926-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2016-02-25 — — US disclosed
US-20160024021-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE HUTCHISON MEDIPHARMA LIMITED (CN) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052926-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF FGFR3, FGFR1, FGFR4 FGFR1 2/4885FGFR4 3/4885KDR 66/4885
US-20160024021-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE FGFR3, FGFR1, FGFR4 FGFR1 2/4885FGFR4 3/4885KDR 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback